China
· Delayed Price · Currency is CNY Sichuan Biokin Pharmaceutical Co.,Ltd. Statistics
Total Valuation
Sichuan Biokin Pharmaceutical Co.,Ltd. has a market cap or net worth of CNY 62.77 billion. The enterprise value is 58.03 billion.
| Market Cap | 62.77B |
| Enterprise Value | 58.03B |
Important Dates
The next estimated earnings date is Thursday, October 31, 2024.
| Earnings Date | Oct 31, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Sichuan Biokin Pharmaceutical Co.,Ltd. has 401.00 million shares outstanding. The number of shares has increased by 5.11% in one year.
| Shares Outstanding | 401.00M |
| Shares Change (YoY) | +5.11% |
| Shares Change (QoQ) | -0.08% |
| Owned by Insiders (%) | 77.13% |
| Owned by Institutions (%) | 10.92% |
| Float | 60.95M |
Valuation Ratios
The trailing PE ratio is 14.88 and the forward PE ratio is 18.18.
| PE Ratio | 14.88 |
| Forward PE | 18.18 |
| PS Ratio | 10.80 |
| PB Ratio | 13.00 |
| P/FCF Ratio | 13.43 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.42, with an EV/FCF ratio of 12.42.
| EV / Earnings | 13.77 |
| EV / Sales | 10.00 |
| EV / EBITDA | 13.42 |
| EV / EBIT | 13.64 |
| EV / FCF | 12.42 |
Financial Position
The company has a current ratio of 2.97, with a Debt / Equity ratio of 24.06.
| Current Ratio | 2.97 |
| Quick Ratio | 2.82 |
| Debt / Equity | 24.06 |
| Debt / EBITDA | 0.27 |
| Debt / FCF | 0.25 |
| Interest Coverage | 147.81 |
Financial Efficiency
Return on equity (ROE) is 155.17% and return on invested capital (ROIC) is 74.88%.
| Return on Equity (ROE) | 155.17% |
| Return on Assets (ROA) | 60.11% |
| Return on Capital (ROIC) | 74.88% |
| Revenue Per Employee | 2.56M |
| Profits Per Employee | 1.86M |
| Employee Count | 2,086 |
| Asset Turnover | 1.31 |
| Inventory Turnover | 1.70 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +85.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +85.30% |
| 50-Day Moving Average | 170.33 |
| 200-Day Moving Average | 147.52 |
| Relative Strength Index (RSI) | 33.97 |
| Average Volume (20 Days) | 675,056 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sichuan Biokin Pharmaceutical Co.,Ltd. had revenue of CNY 5.80 billion and earned 4.21 billion in profits. Earnings per share was 10.52.
| Revenue | 5.80B |
| Gross Profit | 5.56B |
| Operating Income | 4.26B |
| Pretax Income | 4.40B |
| Net Income | 4.21B |
| EBITDA | 4.32B |
| EBIT | 4.26B |
| Earnings Per Share (EPS) | 10.52 |
Balance Sheet
The company has 5.90 billion in cash and 1.16 billion in debt, giving a net cash position of 4.74 billion or 11.82 per share.
| Cash & Cash Equivalents | 5.90B |
| Total Debt | 1.16B |
| Net Cash | 4.74B |
| Net Cash Per Share | 11.82 |
| Equity (Book Value) | 4.83B |
| Book Value Per Share | 12.04 |
| Working Capital | 4.23B |
Cash Flow
In the last 12 months, operating cash flow was 4.74 billion and capital expenditures -63.25 million, giving a free cash flow of 4.67 billion.
| Operating Cash Flow | 4.74B |
| Capital Expenditures | -63.25M |
| Free Cash Flow | 4.67B |
| FCF Per Share | 11.65 |
Margins
Gross margin is 95.79%, with operating and profit margins of 73.33% and 72.61%.
| Gross Margin | 95.79% |
| Operating Margin | 73.33% |
| Pretax Margin | 75.82% |
| Profit Margin | 72.61% |
| EBITDA Margin | 74.41% |
| EBIT Margin | 73.33% |
| FCF Margin | 80.52% |
Dividends & Yields
Sichuan Biokin Pharmaceutical Co.,Ltd. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 0.57% |
| Buyback Yield | -5.11% |
| Shareholder Yield | -5.11% |
| Earnings Yield | 6.72% |
| FCF Yield | 7.44% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |